Key Highlights
- Oxford Biomedica (LSE:OXB) fell 5.15% on 2 September 2026, closing at 424p, following an even sharper sell-off of almost 15% on 1 September.
- The immediate pressure came from safety-related pauses to autoimmune CAR-T clinical programmes being developed by two major customers, Novartis and Bristol Myers Squibb.
- The market reaction appears significantly stronger than the likely direct financial impact on Oxford Biomedica, because the company operates primarily as a contract development and Manufacturing organisation rather than as the developer of these therapies.
- Oxford Biomedica reported approximately £80 million of H1 2026 revenue, up around 9%, alongside a record 17 new clients.
- Revenue Backlog remained substantial at approximately £193 million, while around £165 million of expected 2026 Revenue was covered by contracted client orders.
- The company has nevertheless reduced its FY2026 revenue expectations because some customers are taking longer to place orders and work packages are being staged.
- Oxford Biomedica continues to target FY2026 revenue of approximately £220–240 million, with an operating EBITDA Margin above 10%.
- A five-year commercial Supply agreement with Bristol Myers Squibb remains an important structural positive, with commercial manufacturing expected to begin in 2026 subject to regulatory approvals.
- Investors are now looking closely at the 22 September 2026 half-year results, customer ordering patterns, the impact of CAR-T safety concerns and progress toward profitability.
Why Oxford Biomedica Is in Focus
Oxford Biomedica has suddenly become one of the more closely watched healthcare stocks in London because the company's share price is being caught between two very different narratives.
The first is a strong Long-term Growth story. Oxford Biomedica is building a global CDMO Business focused on viral-vector manufacturing for cell and gene therapies. The company has expanded its manufacturing footprint, increased its AAV capabilities and won additional business from major pharmaceutical and biotechnology companies.
The second is a near-term execution and sentiment problem. In August, the company warned that customer ordering behaviour had shifted, resulting in an update to FY2026 expectations. Then, on 1 September, concerns surrounding autoimmune CAR-T programmes involving two of its customers triggered a much larger sell-off.
That combination has created a sharp reassessment of OXB.
The stock closed at 424p on 2 September, down 23p or 5.15%, with trading Volume running substantially above recent daily levels. The decline came immediately after a fall of approximately 14.7% on 1 September, meaning the shares lost a significant amount of value over just two sessions.
Why Did LSE:OXB Fall 5.15% on 2 September 2026?
The most important Factor was the continuing market reaction to developments involving Novartis and Bristol Myers Squibb.
Both companies have been working on CAR-T approaches for autoimmune diseases. They voluntarily paused enrolment in certain programmes following safety concerns.
Novartis reported three patient deaths across several Clinical Trials of its rap-cel programme, following cases involving a rare and potentially serious immune-related condition. Bristol Myers Squibb separately paused its autoimmune CAR-T programme following inflammatory events.
Because both companies are customers of Oxford Biomedica, investors immediately questioned whether the developments could affect future manufacturing demand.
That concern explains the unusually large sell-off.
However, there is an important distinction: a clinical-trial pause is not the same as cancellation of Oxford Biomedica's manufacturing relationship.
Oxford Biomedica's business is diversified across multiple clients, programmes and viral-vector technologies. Its near-term revenue drivers are not dependent solely on autoimmune CAR-T.
Market commentary following the sell-off argued that the magnitude of the decline appeared disproportionate to the immediate financial exposure, particularly because autoimmune indications represented only a portion of Oxford Biomedica's broader programme portfolio.
The Bigger Issue: Investors Were Already Nervous
The September sell-off did not occur in isolation.
Oxford Biomedica had already experienced a major share-price reaction following its 7 August 2026 trading update.
H1 revenue increased approximately 9% to around £80 million, but management acknowledged that some customers were taking a staged approach to ordering work packages. As a result, the timing of revenue recognition was becoming less predictable.
The company therefore updated its FY2026 expectations while maintaining its broader long-term growth strategy.
This matters because OXB's valuation depends heavily on the assumption that its large pipeline of programmes converts into manufacturing revenue as therapies move through clinical development and toward commercialisation.
If customers delay orders, revenue can move between reporting periods even when underlying Demand remains healthy.
That creates a difficult environment for a growth stock.
Commercial Momentum Remains a Major Positive
Despite the share-price weakness, Oxford Biomedica's underlying commercial indicators remain important.
During H1 2026, the company signed 17 new clients, more than 30% above the total number signed during the whole of FY2025.
The revenue backlog stood at approximately £193 million, providing meaningful visibility into future contracted revenue.
Contracted client orders were approximately £97 million during the first half, while around £165 million of forecast 2026 revenue was covered by existing contracted client orders.
The company's non-risk-adjusted new-business pipeline also increased approximately 30% year-on-year to around $713 million.
This is one of the strongest arguments against interpreting the recent share-price decline as a deterioration of the entire business model.
The issue is increasingly about timing, conversion and programme risk, rather than an absence of demand.
Bristol Myers Squibb Relationship Remains Important
One of the most important developments for OXB in 2026 was the expansion of its relationship with Bristol Myers Squibb.
Oxford Biomedica signed a new multi-year commercial supply agreement to manufacture and supply lentiviral vectors for BMS CAR-T programmes.
The agreement has an initial five-year term with an option to extend, and commercial manufacturing is expected to begin in 2026, subject to regulatory approval of the relevant therapies. Manufacturing is expected to take place across Oxford Biomedica's UK and US facilities.
This agreement is strategically significant because it demonstrates the transition of Oxford Biomedica from a business heavily exposed to early-stage development work toward a more diversified CDMO with late-stage and commercial manufacturing opportunities.
However, the current CAR-T safety concerns mean investors will now pay greater attention to exactly which programmes are affected and whether any manufacturing schedules change.
Importantly, a pause in a particular clinical programme does not automatically invalidate the broader commercial relationship.
Oxford Biomedica's Transformation Into a Global CDMO
The company's Investment case is increasingly centred on becoming a larger, integrated global manufacturing partner for advanced therapies.
In 2025, Oxford Biomedica acquired an FDA-approved commercial-scale viral-vector manufacturing Facility in Durham, North Carolina. That transaction materially expanded its US manufacturing capabilities, particularly in AAV.
The company also increased its ownership of its US business and strengthened its Balance Sheet through financing arrangements and an Equity placing.
At the end of 2025, Oxford Biomedica reported approximately £96.9 million of cash and £55.4 million of net cash.
By 30 June 2026, gross cash had reduced to approximately £75 million and net cash to around £21 million, reflecting continued investment and operational spending.
This is an important area for investors to monitor because the company is simultaneously pursuing aggressive growth and moving toward sustainable profitability.
The £500 Million Long-Term Ambition
At its June 2026 Capital Markets Event, Oxford Biomedica outlined an ambition to reach approximately £500 million of revenue by 2030.
Management's strategy is based on its multi-vector platform, expanded international manufacturing network, technical expertise and relationships with major pharmaceutical companies.
The company operates across key viral-vector technologies including lentiviral vectors and AAV, giving it exposure to multiple areas of cell and gene therapy rather than relying on a single technology.
The long-term opportunity is significant.
Cell and gene therapies require highly specialised manufacturing processes, regulatory expertise and increasingly sophisticated viral-vector production. As therapies move from research into clinical and commercial stages, specialist CDMOs can potentially capture a growing portion of the value chain.
What Investors Will Watch on 22 September
The next major scheduled event is the H1 2026 results on 22 September 2026.
The results will be particularly important because investors will want clarity on four issues.
First, customer ordering behaviour.
The market needs evidence that the recent staging and delays in customer orders are temporary rather than a sign of a broader slowdown.
Second, the revenue outlook.
Investors will assess whether Oxford Biomedica remains firmly positioned to deliver its FY2026 revenue target and whether the £220–240 million range remains achievable.
Third, profitability.
Management has targeted an operating EBITDA margin above 10% in FY2026, followed by at least 20% in FY2027.
The market will want evidence that revenue growth is translating into operating leverage.
Fourth, the CAR-T situation.
Investors will seek greater visibility on the programmes involving Novartis and Bristol Myers Squibb and whether the recent safety concerns could alter manufacturing schedules or longer-term demand.
Why Investors May Still Watch LSE:OXB
The recent decline has clearly damaged short-term sentiment, but the underlying investment case has not disappeared.
Oxford Biomedica has a growing customer base, a large revenue backlog, expanding manufacturing capacity and an increasingly diversified programme portfolio.
The company also has relationships with some of the world's largest pharmaceutical companies.
The key question is whether these strengths can translate into predictable revenue growth and sustainable cash generation.
That is particularly important after the company experienced significant share-price appreciation earlier in 2026 before subsequently falling sharply.
The current valuation therefore reflects a much more cautious market view.
Key Risks
The biggest risk is programme concentration and clinical development uncertainty. CDMOs benefit when client therapies progress, but delays or failures can affect manufacturing schedules.
Another risk is customer ordering volatility. A large backlog does not necessarily mean all revenue will be recognised immediately.
There is also execution risk from expanding manufacturing capacity across the UK and US.
Cash generation remains another important consideration because Oxford Biomedica is investing heavily while attempting to move toward higher margins.
Finally, the latest CAR-T developments highlight a broader sector risk: regulatory or safety concerns can affect the pace at which cell and gene therapies reach commercialisation.
Potential Catalysts Ahead
Several developments could potentially improve sentiment.
The first is stronger-than-expected H2 customer ordering.
The second is successful commercial manufacturing commencement under major customer agreements.
The third is additional large contracts, particularly in AAV and lentiviral vectors.
The fourth is evidence that the Durham facility is being efficiently utilised.
The fifth is improving operating EBITDA and cash generation.
Most immediately, the 22 September interim results could provide the market with the information required to determine whether the recent sell-off represents a fundamental deterioration or an exaggerated reaction to sector-specific news.
Bottom Line
Oxford Biomedica's 5.15% decline on 2 September 2026 to 424p represents another difficult session for a stock already under pressure.
The immediate catalyst was concern surrounding autoimmune CAR-T programmes involving two major customers, Novartis and Bristol Myers Squibb. The previous day's much larger fall shows how aggressively investors have reassessed the risk.
However, the broader business remains considerably more diversified than the recent share-price action might suggest.
Record new-client wins, a roughly £193 million revenue backlog, a substantial order pipeline, the BMS commercial supply agreement and expanding US manufacturing capacity remain important positives.
The investment debate has therefore shifted from simply whether Oxford Biomedica can grow to whether it can convert its strong pipeline into predictable revenue, expanding margins and sustainable cash generation.
For investors watching LSE:OXB, the most important near-term event is the 22 September 2026 half-year results. The quality of the order book, customer timing, profitability trajectory and management's assessment of the recent CAR-T developments could determine whether the current sell-off becomes a longer-term reset or an opportunity for a recovery.
Top of Form
Bottom of Form






Please wait processing your request...